Rheumatoid arthritis (RA) — chronic management & DMARD therapy (seropositive/seronegative; distinct from acute complications)
Bedside summary
Chronic symmetrical inflammatory polyarthritis of small joints (MCP, PIP, wrists, MTP) with synovitis, morning stiffness >30-60 min, RF/anti-CCP positivity (seropositive ~70%) and radiographic erosions. Untreated it causes joint destruction, deformity (ulnar deviation, swan-neck, boutonniere) and excess cardiovascular/lymphoma risk. Core principle = treat-to-target: start conventional synthetic DMARD (csDMARD) early within the 'window of opportunity', aim for remission or low disease activity (DAS28/CDAI), escalate every 3 months until target met. Methotrexate is the anchor drug. This entry is outpatient/initiation management, NOT the acute-complications entry.
Red flags
- Fever + hot swollen joint on immunosuppression — exclude SEPTIC ARTHRITIS (aspirate before assuming flare)
- New neck pain, limb paraesthesia, gait disturbance — atlanto-axial subluxation / cervical myelopathy (image before intubation/GA)
- Breathlessness/cough on methotrexate — MTX pneumonitis or RA-ILD; stop MTX, investigate
- Febrile neutropenia / sepsis on DMARD or biologic — hold immunosuppression, treat as neutropenic sepsis
- Mononeuritis multiplex, skin ulcers, serositis — rheumatoid vasculitis (severe seropositive disease)
Assessment
Differential diagnosis
- Psoriatic arthritis (DIP involvement, dactylitis, nail/skin psoriasis, RF-negative)
- Polymyalgia rheumatica (age >50, proximal girdle, no true synovitis, RF-negative)
- SLE / other CTD arthritis (non-erosive Jaccoud, ANA positive)
- Gout / CPPD polyarthritis (crystal analysis, tophi)
- Viral arthritis (parvovirus B19, hepatitis B/C, chikungunya — self-limiting, RF can be transiently positive)
- Osteoarthritis (DIP/first CMC, bony Heberden/Bouchard nodes, no inflammation)
Investigations
- RF and anti-CCP (anti-CCP more specific, prognostic for erosive disease)
- ESR + CRP (disease activity; part of DAS28)
- FBC, U&E, LFTs (baseline before DMARDs + ongoing monitoring)
- X-rays hands/feet (periarticular osteopenia, erosions, joint space loss) — baseline + progression
- ANA (overlap/mimic screen), hepatitis B/C + HIV serology (before immunosuppression)
- Baseline CXR and consider quantiferon/TB screen before biologics; HBV reactivation risk
- Ultrasound/MRI for subclinical synovitis if diagnosis uncertain
Management
- Confirm diagnosis (2010 ACR/EULAR classification: joints involved + serology + acute phase + duration) and assess disease activity (DAS28/CDAI)
- Start csDMARD monotherapy as soon as diagnosis made — methotrexate first-line unless contraindicated; prescribe folic acid alongside
- Add short-term bridging glucocorticoid (oral taper or IM/IA depot) to control symptoms while DMARD takes effect (6-12 weeks); keep steroid course as short as possible
- Treat-to-target: review at 1-3 months; if target (remission/LDA) not reached by 3-6 months, escalate — step up csDMARD combination or add bDMARD/tsDMARD
- If poor prognostic factors (high activity, erosions, high-titre RF/anti-CCP) and csDMARD failure: add biologic (TNF inhibitor usual first) or JAK inhibitor
- JAK inhibitor: use with caution and prefer a biologic if age >=65, smoker, prior MACE/VTE or malignancy risk (ORAL Surveillance signal)
- Monitor DMARD toxicity on schedule (FBC/LFT/U&E), vaccinate (pneumococcal, annual influenza, avoid live vaccines on biologics), manage CV risk and osteoporosis
- Counsel on pregnancy planning: stop methotrexate + leflunomide (teratogenic) pre-conception; hydroxychloroquine, sulfasalazine, azathioprine, certolizumab are pregnancy-compatible
Drugs & doses
Disposition
Complications & pitfalls
- Joint destruction, deformity and disability
- RA-interstitial lung disease, pleuritis, rheumatoid nodules
- Accelerated atherosclerosis — leading cause of excess mortality
- Cervical spine (atlanto-axial) instability
- Felty syndrome (RA + splenomegaly + neutropenia), secondary Sjogren, amyloidosis
- Increased lymphoma risk; infection risk from immunosuppression
Exam pearls
- Treat-to-target with early methotrexate is the backbone of both ACR 2021 and EULAR 2022/2023 recommendations — do not delay DMARD waiting for specialist if diagnosis clear.
- ACR 2021: methotrexate monotherapy strongly preferred first-line even in moderate-high activity; EULAR: MTX + short glucocorticoid bridge.
- EULAR 2022/2023: bDMARD preferred over JAK inhibitor if risk factors for malignancy/MACE/VTE (post ORAL Surveillance).
- Always flag cervical spine (atlanto-axial subluxation) before any intubation/general anaesthetic in long-standing RA.
- Folic acid is mandatory co-prescription with methotrexate; check FBC/LFT/U&E per local shared-care protocol.
- A single acutely hot joint in RA is septic arthritis until proven otherwise — aspirate, do not just uptitrate steroid. [verify local]
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.